Inferior Vena Cava Filters Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Permanent IVC filter, Retrievable IVC filter, Others), By End User (Hospitals, Ambulatory surgical centers, Others) and By Region Forecast 2020-2031

Inferior Vena Cava Filters Market size was valued at US$ 953.2 million in 2024 and is expected to reach US$ 1,393,172.5 million by 2031, growing at a significant CAGR of 8.9% from 2025-2031. The market is a device implanted in the inferior vena cava, the largest vein in the human body. The inferior vena cava filter is inserted below the kidneys to prevent the risk of pulmonary embolism (PE) and deep vein thrombosis (DVT) when anticoagulation therapy is contraindicated in the patients. The market works by permitting the blood to flow around the trapped clot.  The commercially available inferior vena cava filters include temporary filters and pulmonary filters. The global IVC filter market is growing at a healthy CAGR owing to an increase in the prevalence of deep vein thrombosis.

According to the International Society of Thrombosis and Haemostasis, Inc. (ISTH), approximately 10 Mn cases of venous thromboembolism occur annually around the globe. The most commonly adopted strategies by industry players include new product launches with technological advances, new product approvals, acquisitions & mergers, agreements, and collaborations to capture significant venous thromboembolism market share. acquired Angiotech Interventional Business for the development of the inferior vena cava product portfolio. Moreover, favorable initiatives by regulatory bodies are also expected to boost the IVC market. 

Key Developments

• In December 2022, Zylox-Tonbridge Medical Technology Co. Ltd. received marketing authorization in China for its retrievable IVC filter, Zylox Octoplus, intended to prevent deep vein thrombosis and pulmonary embolism.
• In June 2022, Cordis-X announced an $11.5 million Series F investment in Adient Medical, a company developing a next-generation absorbable IVC filter aimed at preventing pulmonary embolisms. ?
• In December 2012, Volcano Corporation acquired Crux Biomedical to develop its inferior vena cava product portfolio. Similarly,
• In April 2013, Argon Medical Devices, Inc. 
• In May 2014, FDA released the post-market surveillance of IVF filters which provides the implementation of filters and the risk of pulmonary embolism.